Dyspnoea in the GLOBAL LEADERS trial - Authors' reply

Affiliations

¹ Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.
² Jessa Ziekenhuis, Faculty of Medicine and Life Sciences at the Hasselt University, Hasselt, Belgium.
³ Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
⁴ Erasmus Medical Center, Rotterdam, Netherlands; Academic Medical Center of Amsterdam, Amsterdam, Netherlands.
⁵ Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. Electronic address: stephan.windecker@insel.ch.

Comment

Peter Jüni et al. Lancet. 2019.

. 2019 Jun 15;393(10189):2393-2394.

doi: 10.1016/S0140-6736(19)30685-3.

¹ Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.
² Jessa Ziekenhuis, Faculty of Medicine and Life Sciences at the Hasselt University, Hasselt, Belgium.
³ Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
⁴ Erasmus Medical Center, Rotterdam, Netherlands; Academic Medical Center of Amsterdam, Amsterdam, Netherlands.
⁵ Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. Electronic address: stephan.windecker@insel.ch.

No abstract available

Comment on

Dyspnoea in the GLOBAL LEADERS trial.
Martí D, Sanmartín M. Martí D, et al. Lancet. 2019 Jun 15;393(10189):2393. doi: 10.1016/S0140-6736(19)30697-X. Lancet. 2019. PMID: 31204679 No abstract available.